(III) We lack comprehensive biofluids analyses assessing CSF levels of multiple inflammatory markers along with CSF levels of neurodegenerative/PD-specific biomarkers such as Amyloid-β1-42 (Aβ1-42), total-Tau (t-Tau), phospho-Tau (p181-Tau), neurofilament light chain (NFL), and α-synuclein. This evidence concerns the gene MAPT and Parkinson disease.